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ABSTRACT
Glioblastoma (GBM) is maintained by a small subpopulation of tumor-initiating 
cells (TICs). The arduous assessment of TIC frequencies challenges the prognostic 
role of TICs in predicting the clinical outcome in GBM patients. We estimated the TIC 
frequency in human GBM injecting intracerebrally in mice dissociated cells without 
any passage in culture.
All GBMs contained rare TICsand were tumorigenic in vivo but only 54% of 
them grew in vitro as neurospheres. We demonstrated that neurosphere formation 
in vitro did not foretell tumorigenic ability in vivo and frequencies calculated in vitro 
overestimated the TIC content.
Our findings assert the pathological significance of GBM TICs. TIC number 
correlated positively with tumor incidence and inversely with survival of tumor-
bearing mice. Stratification of GBM patients according to TIC content revealed that 
patients with low TIC frequency experienced a trend towards a longer progression free 
survival. The expression of either putative stem-cell markers or markers associated 
with different GBM molecular subtypes did not associate with either TIC content or 
neurosphere formation underlying the limitations of TIC identification based on the 
expression of some putative stem cell-markers.
INTRODUCTION
Although the past years have witnessed an 
improvement in the understanding of early molecular 
events in malignant primary CNS tumors, and a plethora 
of new therapies targeting these events are now tested 
in clinical trials, effective treatments for most primary 
malignant CNS tumors are still lacking [1]. Among 
high-grade gliomas, glioblastoma (GBM; World 
Health Organization grade IV astrocytoma) [2] is the 
most aggressive primary tumor in adults with dismal 
prognosis. Its treatment is palliative and includes surgery, 
radiotherapy, and concomitant chemotherapy [3].
Tumor heterogeneity depicts the leading feature 
supporting tumor robustness and represents the main 
obstacle to overcome to develop therapeutic strategies. 
It is then essential to establish successful assays enabling 
phenotypic, (epi)genetic and functional identification 
and characterization of tumor subpopulations driving the 
tumorigenesis and delineating clinically relevant targets.
Many cancers (i.e. leukemia, breast, colon, brain, 
prostate, melanoma) depend for their continued growth and 
propagation on a population of cells called cancer stem-
cells (CSCs) or tumor-initiating cells (TICs): these cells 
are slow-dividing, endowed with unlimited proliferation 
capacity, functionally defined by their tumorigenic 
capability when engrafted in mice, unresponsive to 
standard treatments, thus highly competent in repopulating 
the tumor [4–11].
TICs appear to be relatively rare in most human 
cancers, ranging from 0,0001% to 0,1% of the bulk tumor 
cell population [5], [6], [12–15]. However, recent studies 
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report that TICs are frequent, indicating frequencies 
ranging from 25% to 40% [8, 16–18].
Of note, different aspects may influence TIC 
estimate: in vitro cell manipulation before transplantation, 
the use of agents (i.e. matrigel) sustaining tumor cell 
transplantation, the extent of the immunodeficiency of the 
recipient host, the duration of the experimental period for 
tumor formation following tumor cell injection and the 
experimental procedure implemented for TIC isolation. 
With this regard, although the exact contribution of each 
cell-surface marker in identifying the TICs is puzzling and 
unclear, current protocols are still based on the expression 
of putative stem-cell markers that could distinguish a small 
subpopulation of cells with tumorigenic potential from the 
majority of non-tumorigenic cells. In addition, the gold 
standard to determine TIC frequency within a tumor is 
the limiting dilution cell transplantation assay (LDA) 
[19]. Nevertheless, despite several studies regarding TIC 
frequencies, only rarely tumoral cells are transplanted in 
limiting dilution experiments.
The variability in TIC frequencies assessment 
challenges the prognostic role of TICs in predicting 
the clinical outcome in cancer patients. Thus far, the 
prognostic value of TICs has been linked in several types 
of tumors to the presence of stem-related features, such 
as the expression of stem-cell markers, genetic features, 
and tumorsphere formation [20–22]. Similar evidences 
have been reported also in GBM, where stem-cell marker 
expression (i.e. CD133, nestin) [23, 24] and neurosphere 
formation [25] have been associated to clinical outcomes. 
However, data from different groups are controversial, 
since GBM stem-cell marker expression is not always 
associated to a prognostic significance [26].
Here, we specifically estimate GBM TIC frequency 
employing limiting dilution transplantation of cells 
isolated from freshly-dissociated human GBMs. We 
believe that, owing the lack of definitive markers, only 
functional criteria applied on freshly-dissociated human 
GBMs will allow an unbiased assessment of the TIC 
content within parental GBMs. Furthermore, through 
in vitro neurosphere assay we look for the existence of 
any correlation between the sphere-forming capability and 
the in vivo tumorigenic potential of cells from the same 
human sample. Moreover, we investigate the effect of 
in vitro culturing primary GBM cells as neurospheres on 
their TIC content.
RESULTS
TICs from freshly-dissociated GBMs are rare
Immediately after surgical removal, GBM 
specimens (n=28) were enzymatically and mechanically 
dissociated and viable cells immediately injected in the 
mouse brain without any in vitro manipulation to evaluate 
the ability to generate tumors. In parallel, cells were also 
plated in non-adherent serum free stem-cell medium to 
allow neurosphere formation. The 86% of the specimens 
analysed (n=24) was tumorigenic in vivo (Table 1), giving 
rise to tumors phenotypically similar to the parental ones 
(Figure 1A). Of these, the 54% (n=13) were able to give 
rise to spheres in vitro while the remaining 46% (n=11) 
did not (Table 1 and Figure 1B). Interestingly, xenografted 
cells from GBMs with uncoupled sphere-forming capacity 
and tumorigenic ability, once isolated always formed 
GBM in secondary xenotransplantation albeit still failed 
to generate neurospheres in vitro (data not shown). Thus, 
the inability to grow in culture cannot predict in vivo 
tumorigenicity.
Considering LDA as the gold standard to quantify 
the TIC content, we stereotaxically injected serial 
concentrations of freshly-dissociated hGBM cells 
ranging from 105 to 10 cells [10]. LDA was carried to 
completion in 19 out of 24 GBMs (Table 1). We did not 
succeed in assessing the TIC frequency of four specimens 
(hGBM#92, hGBM#93, hGBM#94, hGBM#101, 
hGBM#107) due to the paucity of available cells. 
Tumor formation was monitored for nearly one year as 
a consequence of the long latency requested for tumor 
to arise at the lower cellular doses. TIC frequencies in 
freshly-dissociated hGBMs were highly variable between 
patients, ranging from 1/143 to 1/87599 (Table 2). On 
average, freshly-dissociated hGBMs contained rare TICs, 
as observed in other tumors [15]. Interestingly, also 
freshly-dissociated hGBMs unable to form neurospheres 
in vitro (n=9) comprised a rare, highly variable number of 
TICs (Table 1 and 2).
In vitro culture overestimates TIC content
Next, we assessed TIC frequencies in vitro by 
culturing cells derived from the same freshly-dissociated 
hGBM directly into methylcellulose-containing medium, 
which is able to sustain the growth of cells endowed with 
stemness characteristics [11, 12]. On average, in vitro 
TIC frequency (mean=0.00093; C.I.=0.00026÷0.00334; 
n=12) was 10-fold higher than in vivo frequency 
(mean=0.00007; C.I.=0.00002÷0.00022; n=12) (Paired 
samples t-test: P=0.0014**) (Figure 1C). Furthermore, 
in vitro TIC amount is not portending the extent of in vivo 
TIC frequency (Pearson correlation with r=0.08156; 
P=0.8011ns; n=12) (Figure 1D).
We next asked whether TIC frequencies might be 
modified culturing primary hGBM cells in non-adherent 
serum free stem-cell medium. It has been demonstrated 
that TICs propagated as neurospheres closely mimic the 
genotype, gene expression profile, and biology of the 
parental GBM from which they derive [27]. Thus, we 
propagated cells from additional independent freshly-
dissociated hGBMs as neurospheres (hGBM-NS), and 
performed LDA. hGBM-NS TIC content (mean=0.00105; 
C.I.=0.00037÷0.00298; n=10) was higher than TIC 
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Table 1: Clinical and experimental data of collected GBM patients
Clinical Data MRI Therapy Experimental Data
Patient ID Age Sex Initial 
KPS
PFS OS FU Status Tumor size C/L 
inv
Invas Rad 
Surg
CCRT Neurospheres 
formation
Tumor 
formation 
in vivo
GBM#76 55 M 60 2 2 30 D 82×43 mm N 1 N N N N
GBM#79 78 M 50 nd nd 30 nd 40×50 mm N 2 Y nd N Y
GBM#89 71 M 70 5 12 26 D 34×23 mm N 3 N Y N N
GBM#92 66 F 90 20 20 20 A 23×21 mm N 3 N Y Y Y
GBM#93 59 F 70 nd nd 20 nd 34×34 mm N 1 Y nd Y Y
GBM#94 51 F 90 4 17 20 D 54×40 mm N 1 Y Y N Y
GBM#98 52 M 90 17 20 20 A 25×13 mm N 3 Y N Y Y
GBM#99 65 M 80 nd nd 19 nd 81×50 mm Y 2 N nd N Y
GBM#101 52 F 70 5 13 19 D 51×25 mm N 2 Y Y N Y
GBM#103 63 F 80 19 19 19 A 50×32mm N 2 Y Y N N
GBM#106 48 M 80 nd nd 18 nd 52×45 mm N 3 Y nd N Y
GBM#107 72 M 60 nd 3 18 D 87×44 mm N 1 N Y Y Y
GBM#109 59 F 90 nd nd 17 nd 50×43 mm N 2 Y nd N Y
GBM#110 53 M 90 7 17 17 A 30×36mm N 2 N Y N Y
GBM#115 57 F 90 nd nd 16 nd 59×54 mm Y 1 N nd Y Y
GBM#116 51 M 90 nd nd 16 nd multicentric N multi 
centric
N nd N Y
GBM#119 80 M 70 3 15 15 A 39×37 mm N 2 Y Y Y Y
GBM#121 66 M 80 15 15 15 A 48×42 mm N 3 Y N N N
GBM#122 42 F 90 3 15 15 A 30×16 mm N 1 Y Y Y Y
GBM#124 56 F 90 2 4 15 D multicentric N multi 
centric
N Y Y Y
GBM#125 62 M 90 8 14 14 A 62×31 mm N 2 Y Y N Y
GBM#128 56 M 80 5 8 13 D 62×42 mm Y 1 Y Y Y Y
GBM#130 40 M 90 10 12 12 A 41×23 mm N 3 Y Y Y Y
GBM#132 52 M 90 11 11 11 A 35 x31 mm N 1 Y Y Y Y
GBM#133 54 F 90 6 11 11 A 47×21 mm N 1 Y Y Y Y
GBM#138 54 F 90 11 11 11 A 41×34 mm N 1 Y Y Y Y
GBM#139 79 M 80 3 6 11 D 72×52 mm N 3 Y N N Y
GBM#142 42 M 90 4 10 10 A 39×37 mm N 2 Y N N Y
Surgical specimens together with clinical records were collected from 28 consenting patients after surgery. Pathologists 
classified tumors as primary GBM. Overall patients enrolled in the study were 60% men and 40% women, with a median age 
of 58 years (range, 40-80 years) and a mean Karnofsky performance score of 80 (range 50-90). KPS: Karnofsky performance 
status; PFS: progression free survival; OS: overall survival; FU: follow-up; Status: D= dead, A= alive; nd= data not available; 
C/L inv: contralateral invasion; Invas: invasiveness of the tumor mass where 1 = distance of invasion < 2 × diameter of tumor 
mass; 2 = 2 × diameter of tumor mass < distance of invasion < 3 × diameter of tumor mass; 3 = 3 × diameter of tumor mass 
< distance of invasion; Rad Surg: radical surgery (Y= patients that underwent radicl surgery; N= patients that did not undergo 
radical surgery); CCRT: concurrent chemoradiotherapy. In the “experimental data” section are reported the success (Y=Yes) or 
failure (N=No) of neurospheres formation and in vivo tumor development of each collected sample.
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Figure 1: Dissociation between sphere-forming capacity and tumorigenic ability of freshly-dissociated hGBMs. 
A. IHC analysis of a representative human GBM and its correspondent xenograft. The upper part of the panel depicts H&E 
and Nestin antibody staining of human glioblastoma; in the lower part, H&E and Nestin antibody staining of its correspondent 
xenograft are shown. Human anti-nuclei (α–hNU) antibody staining of the xenograft demonstrates the human origin of the tumor. 
Scale bars = 5 μm (H&E and Nestin), 20 μm and 10 μm (hNu). B. The graph represents the in vitro sphere formation ability and 
the in vivo tumorigenicity capacity of freshly-dissociated hGBMs: the 86% (n=24) of the specimens analysed are tumorigenic 
in vivo and the 54% (n=13) of these are able to give rise to spheres when placed in cultured. The remaining 11 specimens (46%) 
present an uncoupled sphere-forming capacity and tumorigenic ability, since they do not succeed to generate in vitro neurospheres. 
C. Comparison of TIC frequencies in freshly-dissociated hGBMs of 12 matched samples calculated through in vitro methylcellulose 
assay (mean 0.00093; C.I. 0.00026÷0.00334 after reverse logarithmic transformation) and in vivo limiting dilution assay (mean 
0.00007; C.I. 0.00002÷0.00022 after reverse logarithmic transformation). The in vitro TIC frequency results to be 10-fold higher than 
the in vivo frequency (Paired samples t-test: t=4.233; df=11; P=0.0014**). D. Representation of the absence of correlation between 
TIC frequencies assessed through in vivo and in vitro assays of the 12 matched samples illustrated in Figure 1C (Pearson correlation 
after logarithmic transformation with r=0.391; P=0.209ns; n=12). E. Comparison of TIC frequencies assessed in freshly dissociated 
hGBMs (mean 0.00012; C.I. 0.00004÷0.00033 after reverse logarithmic transformation; n=19) and in hGBM-NS (mean 0.00105; C.I. 
0.00037÷0.00298 after reverse logarithmic transformation; n=10) through in vivo LDA: TIC content in hGBM-NS was remarkably 
higher (Unpaired Student t-test: t=2.935, df=27, P=0.0067**). All statistical tests are two-sided.
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Table 2: TIC frequencies in freshly-dissociated hGBMs
Freshly-dissociated 
hGBMs
Number of Transplanted Cells TIC Frequency−1
(95% CI)
105 104 103 102 Estimate
hGBM#79
Incidence 3/3 3/3 3/3 1/3 216
Median 
Survival 66±8 60±2 103±0 168±51 (49-962)
hGBM#98
Incidence 1/2 2/3 0/3 52571
Median 
Survival 334±0 319±0 377±0 (12418-222619)
hGBM#99
Incidence 2/2 1/3 3/3 6297
Median 
Survival 122±3 215±107 155±23 (1769-22420)
hGBM#106
Incidence 3/3 3/3 3/3 1/2 143
Median 
Survival 145±100 343±1 277±15 370±25 (22-918)
hGBM#109
Incidence 2/3 1/3 0/2 0/3 67816
Median 
Survival 106±0 108±4 289±123 195±71 (19039-241569)
hGBM#110
Incidence 1/3 2/3 0/2 0/3 87599
Median 
Survival 185±69 255±97 318±62 354±42 (23252-330030)
hGBM#115
Incidence 3/3 3/3 1/3 2164
Median 
Survival 179±5 192±10 195±10 (487-91614)
hGBM#116
Incidence 1/2 2/3 0/3 0/3 52680
Median 
Survival 314±13 301±48 221±0 356±0 (12466-222628)
hGBM#119
Incidence 3/3 3/3 3/3 0/3 417
Median 
Survival 179±12 167±6 203±10 324±21 (117-1494)
hGBM#122
Incidence 2/3 3/3 0/2 0/2 34826
Median 
Survival 59±5 59±11 212±158 227±137 (9539-127156)
hGBM#124
Incidence 2/3 2/3 2/4 28969
Median 
Survival 138±32 260±75 161±24 (7664-109506)
hGBM#125
Incidence 1/3 1/3 1/3 1/3 66380
Median 
Survival 164±15 288±68 270±6 310±28 (18769-234769)
hGBM#128
Incidence 2/3 0/3 1/3 2/3 38765
Median 
Survival 59±24 196±138 87±104 196±108 (10939-137374)
(Continued )
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frequencies assessed in freshly-dissociated hGBMs 
(mean=0.00012; C.I.=0.00004÷0.00033; n=19) (Unpaired 
t-test: P=0.0067**) (Figure 1E), fluctuating from 1/100 to 
1/6819 (Table 3).
TIC number positively correlates with tumor 
incidence and inversely correlates with survival 
in mouse xenografts
By pooling together the in vivo experiments 
performed with either freshly-dissociated hGBMs 
and hGBM-NS, we analysed the relationship between 
the total number of cells intracerebrally injected in 
immunocompromised mice and tumor incidence. In both 
conditions, we observed an increment of tumor incidence 
increasing the number of injected cells: at the maximum 
cell concentration (105 cells), 100% of incidence was 
measured only with hGBM-NS (Figure 2A), in comparison 
to near 80% of incidence with freshly-dissociated hGBMs 
(Figure 2B) (comparison of tumor incidence reported in 
Figure 2A and 2B: G2 Wilks test where G2=35.14; df=4; 
P<0.0001**). The difference may be due to the smaller 
proportion of TICs within the freshly-dissociated hGBMs 
compared to hGBM-NS (Figure 1E). We thus proceeded 
analysing the relationship between the number of inferred 
TICs of each specimen and the corresponding tumor 
incidence. Interestingly, we obtained mirrored result in 
both hGBM-NS and freshly-dissociated hGBMs: up to 
10 injected TICs, the incidence of the tumors increased 
with the number of injected TICs, while the injection of 
more than 10 TICs resulted in 100% of tumor incidence 
(comparison Figure 2C and 2D: G2 Wilks test where 
G2=0.58; df=4; P=0.97ns). Thus, TICs contained in freshly-
dissociated hGBMs and hGBM-NS and extrapolated 
through in vivo LDA have the same tumorigenic potential.
Next, we compared the Kaplan-Meier plots obtained 
through the injection of the same amount of cells (102, 
103, 104, 105 cells) derived from hGBM-NS and freshly-
dissociated hGBMs. The survival curve of hGBM-NS was 
significantly shorter (Figures 2E and 2H), given the higher 
TIC frequency of hGBM-NS (1:2136) compared to that of 
freshly-dissociated tumors (1:26825) (for 102 cells injected 
Freshly-dissociated 
hGBMs
Number of Transplanted Cells TIC Frequency−1
(95% CI)
105 104 103 102 Estimate
hGBM#130
Incidence 3/3 3/3 2/3 0/3 1072
Median 
Survival 188±10 175±20 201±15 295±29 (267-4312)
hGBM#132
Incidence 2/3 2/3 1/2 0/3 36019
Median 
Survival 73±2 90±2 112±0 158±52 (9951-130386)
hGBM#133
Incidence 3/3 3/3 0/3 0/3 4326
Median 
Survival 120±8 139±0 216±0 186±5 (1237-15139)
hGBM#138
Incidence 2/3 3/3 2/3 0/3 22741
Median 
Survival 110±0 117±13 147±22 120±59 (5519-93718)
hGBM#139
Incidence 3/3 3/3 0/3 0/3 4326
Median 
Survival 170±130 244±1 163±142 315±14 (1237-15139)
hGBM#142
Incidence 3/3 3/3 1/3 0/3 2340
Median 
Survival 290±5 268±15 223±62 234±0 (571-9604)
The TIC frequency is calculated through limiting dilution transplantation of n=19 freshly-dissociated hGBMs. Data show 
the TIC frequency per transplanted cells (estimate, in bold) by means of the extreme limiting dilution analysis function 
assessed by ELDA algorithm (http://bioinf.wehi.edu.au/software/elda/). In the table, the tumor incidence and the survival 
time (in days; mean±SD) of tumor-bearing mice after injection of different concentrations of cells are also indicated.
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n=45+ per group, median survival undefined, P=0.0027** 
by Log-rank test; for 103 cells injected n=43+ per group, 
median hGBM-NS survival=122 days and freshly-
dissociated hGBMs survival=274 days, P=0.0002** 
by Log-rank test; for 104 cells injected n=2+ per group, 
median hGBM-NS survival=101.5 days and freshly-
dissociated hGBMs survival=203 days, P=0.0022** by 
Log-rank test; for 105 cells injected n=34+ per group, 
median hGBM-NS survival=68 days and freshly-
dissociated hGBMs survival=164 days, P<0.0001** by 
Log-rank test). Notably, when either freshly-dissociated 
hGBMs (Figure 2I) and hGBM-NS (Figure 2L) were 
Table 3: TIC frequencies in hGBM-NS
hGBM-NS Number of Transplanted Cells TIC 
Frequency−1
(95% CI)
105 104 103 102 10 Estimate
hGBM#7
Incidence 14/14 5/5 6/7 4/9 0/9 352
Median 
Survival 47±7 52±8 71±11 61±9 0±0 (158-786)
hGBM#8
Incidence 6/6 8/8 7/7 6/11 2/4 100
Median 
Survival 78±10 85±14 112±5 141±14 156±4 (47-206)
hGBM#9
Incidence 5/5 4/4 3/4 2/4 2/4 303
Median 
Survival 93±0 154±33 184±39 196±72 243±16 (96-955)
hGBM#10
Incidence 3/3 3/3 2/3 1/3 1/3 488
Median 
Survival 153±12 174±19 186±29 225±0 165±0 (141-1697)
hGBM#18
Incidence 4/4 6/6 5/6 4/6 3/7 201
Median 
Survival 90±48 80±21 88±15 112±8 114±9 (73-558)
hGBM#20
Incidence 1/2 2/2 1/2 1/2 2712
Median 
Survival 291±0 309±104 217±0 181±0 (514-14315)
hGBM#25
Incidence 2/2 3/4 3/4 1/4 0/4 2942
Median 
Survival 142±0 122±25 149±25 191±0 0±0 (929-9327)
hGBM#27
Incidence 2/4 1/3 1/5 1/5 6070
Median 
Survival 267±34 59±0 225±0 136±0 (2007-18370)
hGBM#154
Incidence 2/3 1/3 0/3 0/3 6819
Median 
Survival 191±1 162±0 0±0 0±0 (1921-24218)
hGBM#155
Incidence 3/3 1/3 1/3 0/3 1350
Median 
Survival 89±18 20±0 92±0 0±0 (318-5735)
The TIC frequency is calculated through limiting dilution transplantation of n=10 hGBM-NS. Data show the TIC frequency 
per transplanted cells (estimate, in bold) by means of the extreme limiting dilution analysis function assessed by ELDA 
algorithm (http://bioinf.wehi.edu.au/software/elda/). In the table, the tumor incidence and the survival time (in days; 
mean±SD) of tumor-bearing mice after injection of different concentrations of cells are also indicated.
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Figure 2: Tumor incidences and survival of mice intracerebrally injected with freshly-dissociated hGBM cells and cells 
from hGBM-NS. The graphs depict the percentage of mice that developed tumours after orthotopic injection of 10, 100, 1000, 10000, 
100000 cells from hGBM-NS cultures A. and freshly-dissociated hGBM cells B. In both conditions, we observe an increment of tumor 
incidence increasing the number of injected cells: at the maximum cell concentration, only the mice transplanted with cells from hGBM-NS 
achieve incidence of 100%. (Comparison A-B: G2 Wilks test where G2 =35.14; df=4; P<0.0001**). C and D. Correlation between tumor 
incidence and number of inferred TICs from hGBM-NS (C) and from freshly-dissociated hGBMs (D) The analysis reveals that tumor 
incidence is 100% both in hGBM-NS and in freshly-dissociated hGBMs where at least 11 TICs were injected (Comparison C-D: G2 Wilks 
test where G2 =0.58; df=4; P=0.97ns). E. and H. Kaplan–Meier analysis comparing mice injected with freshly-dissociated hGBM cells and 
cells from hGBM-NS cultures for (E) 100 cells (P=0.0027** by Log-rank test), (F) 1000 cells (P=0.0002** by Log-rank test), (G) 10000 
cells (P=0.0022** by Log-rank test), and (H) 100000 cells (P<0.0001** by Log-rank test). I. and L. Kaplan–Meier analysis based on the 
number of TICs injected using freshly-dissociated hGBM cells (P<0.0001** by Log-rank test; n=9 to 120) (I) and cells from hGBM-NS 
cultures (P<0,0001** by Log-rank test; n=28 to 105) (L) shows a statistically significant advantage on survival when few TICs are injected. 
M. Kaplan-Meier analysis for progression free survival of a cohort of 13 GBM patients in relation to high TIC frequency (1:200-1:5000; 
n=5) and low TIC frequency (1:20000-1:90000; n=8). GBM patients with low TIC frequency experiences a longer, although not statistically 
significant, progression-free survival (median 7.5 months vs 6 months, P=0.33ns by Log-rank test). Difference between groups is evaluated 
by means of the Log-rank test.
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stratified according to their TIC content, fewer was the 
amount of intracerebrally engrafted TICs, greater was 
mice survival (freshly-dissociated hGBMs: n=9 to 120, 
P<0.0001** by Log-rank test; hGBM-NS: n=28 to 105, 
P<0,0001** by Log-rank test). Similar results were 
obtained by stratification of GBM patients according 
to their TIC content. Given that TIC frequencies vary 
up to 500-fold between patients (Table 2), we divided 
GBM cohort in patients with low TIC content (1:20000-
1:90000; n=8) and high TIC content (1:200-1:5000; n=5). 
Notably, patients with low TIC frequency experienced a 
longer, although not statistically significant, PFS (median 
7.5 months versus 6 months, P=0.33ns by Log-rank test 
(Figure 2M). Interestingly, putative stem-cell markers, 
markers associated with different GBM molecular 
subtypes [28, 29] and common GBM genetic alterations 
were similarly distributed between patients with low and 
high TIC content (Supplementary Figures S1 and S2; 
Supplementary Table S1A). Moreover, no association 
of these markers with neurosphere formation was found 
(Supplementary Table S1B).
DISCUSSION
We established a quantitative assay that enables 
GBM TIC enumeration in human GBMs through direct 
injection of material immediately after the surgical 
procedure. Using this assay, we demonstrate that TICs 
are rare in GBMs. Moreover, TICs number is not uniform 
across patients and it is affected by in vitro culture 
manipulation, which overestimates the real TIC content.
Several research groups gave an estimation of 
GBM TIC frequencies, but these studies mostly relied on 
marker surface expression [12] (i.e. CD133 positive cells) 
or functional properties [9, 10, 30, 31]]. Such approaches 
often led to controversial results, since appropriate 
standardization methods to distinguish glioma stem-cells 
from progenitors or more differentiated cells are still 
lacking [32]. The estimated GBM TIC frequencies known 
in literature are mainly based on neurospheres [11, 12] 
and rarely on acutely dissociated tumors. Of note, the 
maintenance of surgical specimens for few passages, or 
even after one single passage, in a petri dish in serum-
free condition can induce cell selection influencing the 
outcome of the frequency assessment [33]. In addition, 
a proper calculation of TIC frequency is still incomplete 
since tumor cells have been only rarely transplanted in cell 
dilution experiments.
We performed functional assays to determine the 
presence within freshly-dissociated human GBMs, of 
cells that more efficiently transplant the disease, and the 
occurrence of an analogy between TIC number calculated 
in vivo and in vitro. To address in vivo tumor propagation 
potential, we took advantage of an orthotopic xenograft 
model established in immunodeficient CD-1 nude mice 
[10, 34]. Different murine models have been developed 
to study human tumor xenografts, comprising severely 
compromised immunodeficient (SCID) mice, non-obese 
diabetic (NOD)-SCID or NSG mice [8, 15]. However, the 
use of more severely immunocompromised mouse strains 
could considerably increase TIC frequency, a scenario 
quite far from reality. Although the NOG mouse model 
shows markedly better engraftment of some tumoral cells 
than the NOD/SCID mouse [8, 15], according to our 
experience CD-1 mice survival was comparable to NOG 
survival.
We demonstrated that all GBMs analysed in this 
study contain rare TICs sustaining tumor growth, in 
accordance with other studies in GBMs and other types 
of tumors [5, 7, 12, 15, 17, 18]. Our results clearly show 
that not all human GBMs are able to grow in vitro but, 
remarkably, all of them are tumorigenic in vivo. Ex-vivo 
and in vivo experiments performed with cells kept in 
culture exclude from the analysis those GBMs not 
forming neurospheres, which we demonstrated are indeed 
representing a large proportion of tumors. Notably, the 
lack of correlation between tumor formation and ability 
to form neurospheres has been already demonstrated in 
a mouse model of glioma [35] and in a different cohort 
of GBM patients [36] emphasizing the importance of the 
cerebral compartment as a support for TIC growth and of 
in vivo limiting dilution assay on fresh specimens to assess 
the real TIC content.
However, controversial results exist demonstrating 
that in vitro sphere forming potential correlates with the in 
vivo tumorigenic potential in immunocompromised mice, 
as well as the ability to form neurospheres in culture can 
be considered a prognostic factor affecting GBM patient 
survival [25].
Performing a side-by-side analysis of the same 
specimen, we obtained an overestimation of TIC 
number when plating cells in semisolid substrate 
compared to xenotransplanting the same cells in 
immunocompromised mice. The higher TIC frequency 
in vitro is not surprising considering the known ability 
of progenitor cells to clone in vitro as well [10, 12]. In 
addition, the results make evident that the TIC frequency 
calculated through in vitro assays cannot portend the 
in vivo TIC frequency, reinforcing the need to investigate 
the tumor population immediately after surgical 
resection through in vivo LDA. Relevant is also the 
10-fold difference quantified between the average TIC 
frequency of freshly-dissociated hGBMs and the average 
TIC frequency of in vitro maintained neurospheres. 
This different frequency might be explained by the 
composition of the two populations. Data from our 
group [10] and others’ [9, 30] demonstrated, through the 
use of marker-independent methods, that neurospheres 
are mainly composed by slow-dividing cells endowed 
with stem-cells characteristics and high-dividing cells, 
tumorigenic and able to proliferate, although for only 
few rounds.
Oncotarget71500www.impactjournals.com/oncotarget
After the establishment of an accurate estimation 
of TIC number, we explored the TIC influence on tumor 
incidence and mice survival. Interestingly, few studies 
exist only in other types of tumors reporting a relation 
between TIC frequencies and tumor aggressiveness, 
implemented through in vivo LDA in immunodeficient 
recipient mice [15, 37]. In line with these studies, we 
found a positive association between TIC frequency 
and GBM incidence and we defined a threshold over 
10 TICs sufficient to induce tumors in 100% of cases. 
In addition, TIC number inversely correlated with mice 
survival. Notably, GBM patients with low TIC frequency 
experienced a trend towards a longer progression free 
survival. However, we did not find any association 
between the clinical features (tumor size and tumor 
invasiveness) and TIC content. Despite the controversial 
results related to markers clearly describing the TIC 
and their relation with GBM patients’ outcome [23, 24, 
26], the expression of either putative stem-cell markers 
or markers associated with different GBM molecular 
subtypes [28, 29], or common genetic GBM hallmarks 
did not associate with either TIC content or neurosphere 
formation.
TICs derived from human GBMs have been 
characterized mainly in in vitro experiments and their 
effectiveness as informative tools in reflecting GBM 
pathophysiology, determining differentially regulated 
pathways as well as in exploring the potential efficacy of 
anticancer drugs is well recognized. With this study we 
demonstrate that in vivo examination of cells from freshly-
dissociated GBMs in a context that closely resembles the 
original setting will provide an unbiased tool to analyse 
the widest range of GBMs. In addition, we believe that 
the assessed TIC frequency mirrors the real TIC content 
in human GBMs, especially in light of the recent findings 
related to the possible conversion of non-TICs to a TIC 
phenotype, which is dependent on microenvironmental 
cues and that can not be properly simulated in in vitro or 
ex vivo conditions [38–41].
Our findings establish the accuracy of TIC detection 
by injecting freshly-dissociated GBM cells, and the need 
for care when using in vitro cultured neurospheres. The 
orthotopic injection of acutely-dissociated human GBMs 
represents an unbiased pre-clinical tool for basic and 
translational research.
MATERIALS AND METHODS
GBM patients
Surgical specimens and clinical records were 
collected from 28 consenting patients in the Department 
of Neurosurgery at Neurological Institute “C. Besta” 
(Italy) under “C. Besta” research ethics committee 
approval. The specimens were analysed by pathologists 
and classified as primary GBM (WHO IV). Tumors 
displayed characteristics consistent with those reported in 
the literature concerning age, sex distribution, dimensional 
range, Karnofsky performance status scale (KPS) and 
invasiveness [36].
Overall survival and progression-free survival 
have been calculated as elapsed time from surgery to 
death or from surgery to the diagnosis of recurrence/
progression. The patients enrolled in the study were 
60% men and 40% women, with a median age of 58 
years (range, 40-80 years) and a mean Karnofsky 
performance score of 80 (range 50-90). The mean 
follow up was 17 months (range 10-30); 7 patients 
were lost to follow up, whereas for the others mean 
progression free survival (PFS) was 8+/-5.8 months, 
while overall survival (OS) was 11.8+/-5.1 months, in 
accordance to RANO criteria [42]. Tumor invasiveness 
has been calculated as well as was evaluated 
invasiveness in the contralateral hemispheres. Distance 
of infiltration was estimated measuring the oedema area 
in FLAIR sequences in MRI. The majority of selected 
patients received radical surgery and concurrent 
chemoradiotherapy (CCRT).
Tumor sample preparation and in vitro assay
TICs were isolated from GBM surgical specimens 
as previously described [10]. Briefly, fresh tumors were 
finely minced, enzymatically digested with papain (2 mg/
ml; Worthington Biochemical, Lakewood, NJ) at 37°C 
and mechanically dissociated until achievement of single 
cell suspension. To remove red blood cells, the single cell 
suspension was incubated at room temperature for 3 – 5 
minutes with ACK (Ammonium-Chloride-Potassium) 
Lysing Buffer and then separated from debris using 
Percoll density gradient centrifugation. Viable cells were 
resuspended in serum-free medium (Dulbecco’s modified 
Eagle medium/ Ham’s F12 Nutrient Mixture; StemCell 
Technologies) supplemented with B27 supplement (Life 
Technologies, Paisley, United Kingdom; www.invitrogen.
com), 20 ng/ml epidermal growth factor, 10 ng/ml basic 
fibroblast growth factor (PeproTech, Rocky Hill, NJ). 
Human GBM neurospheres were grown as spheroid 
aggregates as previously described [10].
To evaluate the capacity to form neurospheres, cells 
were resuspended in Dulbecco’s modified Eagle medium/
F12 medium containing methylcellulose (StemCell 
Technologies, Vancouver, BC, Canada) and seeded on 
a minimum of three 35 mm culture plates (3000 cells/
dish). Two weeks after plating, the number of clones 
was counted. The ratio between neurospheres formed 
and number of single cells plated corresponds to the 
percentage of TICs in the plate.
In Vivo Limiting Dilution Transplantation Assay
Decreasing cell concentrations (105-10 cells) 
derived from both freshly-dissociated GBM cells and 
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hGBM-NS were resuspended in 2 μl of phosphate-
buffered saline (PBS) and stereotaxically injected into 
the nucleus caudatus (coordinates from bregma: 1 mm 
posterior, 3 mm left lateral, and 3.5 mm in depth) of 5 
weeks old female nu/nu CD1 mice (Charles River, 
Wilmington, MA; http://www.criver.com). Mice were 
intraperitoneally anesthetized with tribromoethanol (0.1 
ml/10 g of body weight). The experiments were performed 
in accordance with the Italian laws (D.L.vo 116/92 and 
following additions), which enforce EU 86/609 Directive 
(Council Directive 86/609/EEC of 24 November 1986 on 
the approximation of laws, regulations and administrative 
provisions of the Member States regarding the protection 
of animals used for experimental and other scientific 
purposes). The mice were maintained until development 
of neurologic signs, and the brains of killed mice were 
collected.
Statistical Analysis
Paired samples t-test was used to compare TIC 
frequency calculated through in vitro methylcellulose 
assay and in vivo LDA on matched freshly-dissociated 
hGBMs. TIC frequency assessed through in vivo LDA 
in freshly-dissociated hGBMs and in hGBM-NS was 
compared performing the unpaired Student t-test. The 
relation between matched values of in vivo/in vitro TIC 
frequency was evaluated by means of correlation analysis. 
For the in vivo LDA, TIC frequency and statistical 
significance were estimated by means of the extreme 
limiting dilution analysis function (http://bioinf.wehi.
edu.au/software/elda/). The incidences of tumors per 
number of injected cells and injected TICs were compared 
by means of Log-linear analysis (G2 test; http://www.
biostathandbook.com/gtestgof.html). In Kaplan–Meier 
curves, survival differences were compared by Log-rank 
test. P-values less than 0.05 were considered statistically 
significant (**) unless otherwise indicated. All statistical 
tests were two-sided.
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